Evidence map›Paper›PMID 41929976›Full record

ArticleJournal of Alzheimer's disease reports

Towards practical application of deep learning in diagnosis of Alzheimer's disease.

Harshit Parmar, Eric Walden, Alzheimer's Disease Neuroimaging Initiative *

Abstract read
In one paragraph

Article in Journal of Alzheimer's disease reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Harshit ParmarTexas Tech Neuroimaging Institute, Texas Tech University, Lubbock, TX, USA.ORCID https://orcid.org/0000-0003-1506-6873
Eric WaldenTexas Tech Neuroimaging Institute, Texas Tech University, Lubbock, TX, USA.
Alzheimer's Disease Neuroimaging Initiative *

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Accurate diagnosis of Alzheimer's disease (AD) is both challenging and time consuming. With a systematic approach to diagnosis, steps can be taken toward improved treatment and prevention of the disease. Objective: This study explores the practical application of deep learning models for the diagnosis of AD across different disease stages. Methods: Due to computational complexity, long training times, and limited availability of labeled datasets, full brain three-dimensional (3D) convolutional neural networks (CNNs) are not commonly used, and many studies rely on two-dimensional (2D) variants. In this work, full brain 3D versions of well-known 2D CNN architectures were designed, trained, and tested for the diagnosis of multiple stages of AD. More than 1500 full brain volumes were used for model training and evaluation. Results: The proposed deep learning approach demonstrated good performance in differentiating various stages of AD. In addition to classification, the models were able to extract discriminative features relevant to disease stage. These features aligned with meaningful anatomical landmarks that are currently considered important for AD identification by clinical experts. An ensemble of all algorithms was also evaluated and achieved superior performance compared to individual models, with a maximum classification accuracy of 87.4%. Conclusions: The trained 3D CNNs and their ensemble show strong potential for assisting in the diagnosis of AD. These models may be incorporated into clinical software tools to support physicians and radiologists in improved diagnostic decision making.

Indexed as

3D CNNAlzheimer's diseasedeep learningmagnetic resonance imaging

Identifiers

PMID41929976
PMCPMC13039045

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.